Showing 51-60 of 10539 results for "".
IL-31’s Role in Prurigo Nodularis
https://practicaldermatology.com/videos/dermatology-hub-neuroimmune-network/il-31s-role-in-prurigo-nodularis/48804/Raj Chovatiya, MD, PhD, MSCI, FAAD, explains the role of the IL-31 pathway in neuroinflammatory disease such as prurigo nodularis.What ’s the Best Approach to AK Therapies? Ask an Expert
https://practicaldermatology.com/topics/skin-cancer-photoprotection/what-s-the-best-approach-to-ak-therapies-ask-an-expert/19622/Rather than consider AK a specific disease, Vishal A. Patel, MD, FAAD says it can be viewed as a marker of disease, which culminates in SCC. In this edition of Ask an Expert with Adam Friedman, MD, about his philosophy of treatment, including long-term maintenance.Physician Spotlight: Robert S. Kirsner, MD, PhD, FAAD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-robert-s-kirsner-md-phd-faad/20319/It's time to get wound up about wound care.DermwireTV — Revance’s Neurotoxin Promising, Celebs Fight Melanoma with L’Oreal
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-mdash-revance-rsquo-s-neurotoxin-promising-celebs-fight-melanoma-with-l-rsquo-oreal/19138/In this weeks DermwireTV, patient safety is explored, L'Oreal supports melanoma research and Revance reports positive data for novel neurotoxin.DermwireTV — Bayer Buys Merck’s OTC Lines, Allergan Rejects Valeant Bid
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-mdash-bayer-buys-merck-rsquo-s-otc-lines-allergan-rejects-valeant-bid/19134/Bayer Purchases Merck's OTC Products and Allergan Rebuffs Valeant. This week DermWireTV explores Bayer's growth in the OTC space, including sunscreens, and reports new data on skin cancer mortality. Also in this edition: Neal Bhatia, MD reviews the Noah Worcester Society Annual Meeting.Three Nevada Med Students Win Practical Dermatology®’s Best Paper of 2019 Award
https://practicaldermatology.com/youngmd-connect/resident-resource-center/three-nevada-med-students-win-practical-dermatologys-best-paper-of-2019-award/23202/The Best Tax Treatment for a Dermatology Practice
https://practicaldermatology.com/topics/practice-management/the-best-tax-treatment-for-a-dermatology-practice/23144/S Corp or C Corp in the post-TCJA world?Staphylococcus aureus Colonization
https://practicaldermatology.com/issues/september-2025/staphylococcus-aureus-colonization/37626/In a recent review article, Piewngam and Otto examined the epidemiology, mechanisms, and clinical implications of Staphylococcus aureus (S. aureus) colonization, while evaluating both current and emerging strategies for decolonization.DermWireTV: AAD's Diversity Plan, Galderma Acne Data, Nutrafol Pro-Strength Boosters
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-aads-diversity-plan-galderma-acne-data-nutrafol-pro-strength-boosters/19903/Kanya Ferguson, MD, FAAD, Chair of the AAD’s Diversity Committee, speaks about the AAD’s new comprehensive, three-year plan focused on Diversity, Equity, and Inclusion. It was approved with unanimous support by the AAD’s Board of Directors. A new survey conducted by Galderma and reScientifically Speaking: Can We Conquer Cellulite?
https://practicaldermatology.com/videos/scientifically-speaking/scientifically-speaking-can-we-conquer-cellulite/19872/Treating cellulite has been a challenge, but new and emerging technologies offer hope to overcome this common condition. Host Joel L. Cohen, MD talks with Nazanin Saedi, MD, Endo's Mike McLane, PhD, and Soliton's Wally Klemp.